Clinical Trials
8 trialsNCT06110793 2026-05-13
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT02562118 2025-09-25
Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT05181033 2025-07-25
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
National University Hospital, Singapore
Phase 2 Recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT06140576 2023-11-20
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
Zhejiang Cancer Hospital
Phase 1/2 Not yet recruiting
NCT02915172 2017-06-26
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03168074 2017-06-16
Phase II Study of Single Agent Lenvatinib
National University Hospital, Singapore
Phase 2 Unknown